[Status and trends in the field of inhibitors of thrombocyte function]
[Article in
German]
- PMID: 6083929
Item in Clipboard
[Status and trends in the field of inhibitors of thrombocyte function]
[Article in
German]
Folia Haematol Int Mag Klin Morphol Blutforsch.
1984.
Abstract
The pharmacological control of platelet functions was discussed. Besides specific receptor antagonists of aggregatory agents, drugs inhibiting the arachidonate metabolism and thus formation of thromboxane A2 proved to be inhibitors of platelet aggregation. Drugs influencing the cAMP level of platelets via activation of adenylate cyclase or inhibition of phosphodiesterase have a broad spectrum of inhibitory effects. By the combined use of inhibitors of platelet function potentiation of their effects is expected.
Similar articles
-
Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.J Pharmacol Exp Ther. 1995 Dec;275(3):1497-505. J Pharmacol Exp Ther. 1995. PMID: 8531121
-
Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.J Pharmacol Exp Ther. 1988 Jul;246(1):301-7. J Pharmacol Exp Ther. 1988. PMID: 3134542
-
Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.Thromb Haemost. 1993 Nov 15;70(5):822-5. Thromb Haemost. 1993. PMID: 8128441
-
[Pharmacology of anti-platelet agents].J Mal Vasc. 1983;8(1):3-16. J Mal Vasc. 1983. PMID: 6302191 Review. French.
-
[Mechanism of action of antiplatelet medication].Sangre (Barc). 1984;29(4-C):817-32. Sangre (Barc). 1984. PMID: 6096974 Review. Spanish. No abstract available.